1952 — Everest Medicines Share News
0.000.00%
Last trade - 00:00- HK$11.47bn
- HK$11.42bn
- CNY1.71bn
Brief: Everest Medicines Announces European Commission Grants Approval Of Kinpeygo For Adults With Primary IgA Nephropathy To Our Partner Calliditas Therapeutics
Brief: Everest Medicines Says Licensing Partner Pfizer Reports Positive Topline Results From Yearlong Phase 3 Trial Of Etrasimod In Ulcerative Colitis Patients
Brief: Everest Medicines Says FY Loss Attributable Rmb1,008.7 Mln Versus Rmb5,658.2 Mln
Brief: Everest Medicines Enters Into Agreement With Calliditas Therapeutics To Develop And Commercialize NEFECON
Brief: Everest Medicines Announces That Licensing Partner Venatorx Pharmaceuticals Reports Positive Results From Pivotal Phase 3 Cefepime-Taniborbactam Trial
Brief: Everest Medicines And Providence Therapeutics Announces That PTX-COVID19-B, A MRNA Vaccine For COVID-19 Has Received Approval For Inclusion In WHO Solidarity Trial Vaccines (STV) Program
Brief: Everest Medicines, Providence Therapeutics Jointly Announce Vaccine Development Strategy To Address Omicron (B.1.1.529) Sars-Cov-2 Variant
Brief: Everest Medicines As Of 5 Nov, Has Repurchased 1.6 Million Shares For About Hk$71 Million
Brief: Everest Medicines Announces Submission Of NDA To Department Of Health Of HK For Xeravatm
Brief: Everest Medicines Announces Approval Of Investigational New Drug Application By China NMPA For SPR206
Brief: Everest Medicines Announces A Multi-Year Research And Develop Collaboration Agreement
Brief: Abcellera And Everest Medicines Announce Multi-Target Collaboration
Brief: Everest Medicines Says Unit Entered Into License Agreement With Sinovent And Sinomab
Everest to bring Canadian biotech's potential COVID shots to China, other markets
Brief: Everest Medicines & Providence Enter Into COVID-19 Vaccines License Agreement
Everest to bring Canadian biotech's potential COVID shots to China, other markets
Brief: Everest Medicines Posts HY Net Loss Of RMB383.1 Million
Brief: Everest Medicine Intents To Conduct On-Market Share Repurchase
Brief: Everest Medicines Says First Person Dosed In Global Phase 3 Registration Trial Of Sacituzumab Govitecan-Hziy